Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.

You may also be interested in...

NICE Rejects Pierre Fabre’s Javlor, Citing Basic Evidence Errors

Britain’s NICE has turned down Pierre Fabre’s Javlor for cancer of the urothelial tract, saying the French company’s basic trial structure did not meet its requirements.

NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs

Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts